Quanterix, Akoya Biosciences announce amended merger agreement

Quanterix (QTRX) and Akoya Biosciences (AKYA) announced an amendment to the terms of their previously announced merger agreement. Under the amended terms, Quanterix will issue approximately 7.76M shares of its common stock and pay $20M in cash to Akoya shareholders. Each Akoya share will receive $0.38 per share in cash and 0.1461 shares of Quanterix common stock. With the amended exchange ratio, Quanterix will issue over 9M fewer shares than under the original deal terms. Quanterix shareholders will own approximately 84% of the combined company and Akoya shareholders will own approximately 16%. The revised transaction terms and amended merger agreement have been approved by the Quanterix Board and the Akoya board, respectively. Shareholders of Akoya who hold more than 50% of Akoya’s common stock have agreed to vote in favor of the merger on the amended terms. As a result of the amended merger agreement, Quanterix will no longer hold its previously announced special meeting of shareholders. The transaction is expected to close during the second quarter of 2025, subject to the approval of Akoya shareholders and satisfaction of other customary closing conditions.